A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy

Next Previous
Trial Profile

A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Multiple myeloma; T cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms VEG-VCA1

    • Most Recent Events

    • 14 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top